Key risks
- ROE of 9.94% suggests capital is not generating competitive returns relative to typical pharma benchmarks — verify if this reflects transitional investments or structural capital efficiency issues.
- Consolidated operating margin of 19.8–20.56% over recent quarters leaves limited buffer against input-cost inflation or pricing pressure — verify vulnerability to commodity or FX shocks.
- PE of 25.38 implies market is pricing in growth; a miss on revenue or earnings would correct sharply, especially given 1y rally of 51.65% from lower base.
- Standalone quarterly revenue flat at ₹2,750–₹2,800 Cr despite consolidated growth — verify whether standalone segment is mature or facing headwinds.
Generated analysis · source review pending